---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-004562"
form_type: "8-K"
ticker: "HBIO"
cik: "0001123494"
company_name: "HARVARD BIOSCIENCE INC"
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:41:17.615342+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Harvard Bioscience Q2 revenue $23.1M (-20% YoY); GAAP net loss $2.9M

## Summary
- Q2 revenue $23.1M, down 20% from $28.8M; gross margin 57.2% vs 58.0%.
- GAAP operating loss $2.1M vs income $0.8M; diluted GAAP EPS -$0.07 vs -$0.02.
- Adjusted EBITDA $1.3M (5.5% margin) vs $3.9M (13.6%); adjusted EPS $0.00.
- Q2 cash from operations $0.6M vs $5.4M; cost actions expected to save $4M annually.
- CEO cites challenging market with recovery delayed to later in second half.

## SEC filing metadata
- accession: 0001171843-24-004562
- form_type: 8-K
- ticker: HBIO
- cik: 0001123494
- company_name: HARVARD BIOSCIENCE INC
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1123494/000117184324004562/0001171843-24-004562-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1123494/000117184324004562/f8k_080824.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-004562
- JSON: https://secwatch.observer/filing/0001171843-24-004562.json
- Plain text: https://secwatch.observer/filing/0001171843-24-004562.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.